Key result
Cardiac gene transfer targeting calcium cycling proteins provides a potential therapeutic modality and an approach to identifying and validating molecular targets in heart failure.
Cardiac gene transfer provides a potential therapeutic modality and an approach to identifying and validating molecular targets in heart failure.
Hypothesis-generating for calcium cycling gene transfer in HF; prospective trials needed before clinical adoption.
Our understanding of cardiac excitation-contraction coupling has improved significantly over the last 10 years. Furthermore, defects in the various steps of excitation-contraction coupling that characterize cardiac dysfunction have been identified in human and experimental models of heart failure. The various abnormalities in ionic channels, transporters, kinases and various signalling pathways collectively contribute to the 'failing phenotype.' However, deciphering the causative changes continues to be a challenge. An important tool in dissecting the importance of the various changes in heart failure has been the use of cardiac gene transfer. To achieve effective cardiac gene transfer a number of obstacles remain, including appropriate vectors for gene delivery, appropriate delivery systems, and a better understanding of the biology of the disease. In this review, we will examine our current understanding of these various factors. Gene transfer provides not only a potential therapeutic modality but also an approach to identifying and validating molecular targets.
No takes yet. Share an insight, caveat, or question.
Monte et al. (2003) conducted a review in Heart failure. Cardiac gene transfer was evaluated. Cardiac gene transfer targeting calcium cycling proteins provides a potential therapeutic modality and an approach to identifying and validating molecular targets in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: